Summary List PlacementBiotech investors are flooding into the mental health and neuroscience fields, and RA Capital is the latest to get in on the trend. The venture capital firm launched Eliem Therapeutics on Thursday, after combining two biotechs it had been incubating for several years. Eliem raised a $39 million Series A extension round at a $145 million valuation, according to three sources, who asked not to be identified as they were not authorized to discuss financials publicly. Eliem now has $80 million in capital, which is expected to fund it through 2022, according to an investor at RA Capital.